Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study.

Area of Science:

• Neurology
• Pharmacology

Background:

• Spasticity is a common and disabling symptom in multiple sclerosis (MS).
• Baclofen is a muscle relaxant often used to manage spasticity.

Observation:

• This study evaluated the long-term safety and efficacy of baclofen in MS patients.
• The study monitored hepatologic, hematopoietic, and renal function over time.

Findings:

• Baclofen demonstrated a safe profile with no observed toxic effects on major organs, even after 3 years.
• Significant reductions in spasm frequency and clonus were observed.
• Improved joint mobility and maintained functional status were noted in patients treated with baclofen.
• Symptomatic relief from painful spasms and increased tolerance to immobility were reported, especially in severely disabled patients.

Implications:

• Baclofen is a safe and effective therapeutic option for managing multiple sclerosis-related spasticity.
• Early intervention with baclofen may optimize patient outcomes and prevent permanent disability.
• Maintaining functional status and alleviating pain can significantly improve the quality of life for MS patients.